Benefit/risk profile of dapagliflozin 5 mg in theDEPICT-1 and-2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m2

AIM: The DEPICT-1 and -2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin in individuals with type 1 diabetes who were receiving intensive insulin therapy. The DEPICT-1 and -2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin i...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	DIABETES OBESITY & METABOLISM 2020-11, Vol.22 (11), p.2151-2160
Hauptverfasser:	Mathieu, Chantal, Dandona, Paresh, Birkenfeld, Andreas L, Hansen, Troels Krarup, Iqbal, Nayyar, Xu, John, Repetto, Enrico, Scheerer, Markus Florian, Thoren, Fredrik, Phillip, Moshe
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!